Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4) PR Newswire GERMANTOWN, Md., Oct. 3, 2019 GERMANTOWN...
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...
Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients PR...
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washing...
Neuralstem Reports Second Quarter 2019 Fiscal Results PR Newswire GERMANTOWN, Md., Aug. 14, 2019 GERMANTOWN, Md., Aug. 14, 2019 /PRNewswire/...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing PR Newswire GERMANTOWN, Md., Aug. 7, 2019 GERMANTOWN, Md., Aug...
Neuralstem Closes $7.5 Million Underwritten Public Offering PR Newswire GERMANTOWN, Md., July 31, 2019 GERMANTOWN, Md., July 31, 2019...
Filed Pursuant to Rule 424(b)(4) Registration No. 333-232273 PROSPECTUS ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF...
Neuralstem Announces Pricing of $7.5 Million Underwritten Public Offering PR Newswire GERMANTOWN, Md., July 25, 2019 GERMANTOWN, Md., July 25...
As filed with the Securities and Exchange Commission on July 25, 2019 Registration...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads